Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	Adverse events (solicited; unsolicited and SAEs) reported during the study in the two groups <br/ > <br/ >Seroconversion rate based on IgG antibodies against S1 antigen (by ELISA) at Day 56. <br/ >Timepoint: Day 56	Adverse events (solicited; unsolicited and SAEs) reported during the study in the two groups <br/ > <br/ >Seroconversion rate based on IgG antibodies against S1 antigen (by ELISA) at Day 56. <br/ >Timepoint: Day 56
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
March 26, 2021, 2:21 p.m.	oms	Adverse events (solicited; unsolicited and SAEs) reported during the study in the two groups <br/ > <br/ >Seroconversion rate based on IgG antibodies against S1 antigen (by ELISA) at Day 56. <br/ >Timepoint: Day 56	Adverse events (solicited; unsolicited and SAEs) reported during the study in the two groups <br/ > <br/ >Seroconversion rate based on IgG antibodies against S1 antigen (by ELISA) at Day 56. <br/ >Timepoint: Day 56